Lentinan Promotes Maturation and Function of Dendritic Cells of Acute Myeloid Leukemia Patients
WANG Yu-hong,ZHANG Lian-sheng,CHAI Ye,ZENG Peng-yun,SONG Fei-xue,YUE Ling-ling,LI Li-juan,WU Chong-yang,YI Liang-cai,LIU Ying
DOI: https://doi.org/10.3872/j.issn.1007-385x.2010.04.014
2010-01-01
Chinese Journal of Cancer
Abstract:Objective:To study the effects of lentinan(LNT)on maturation and function of dendritic cells(DCs)of acute myeloid leukemia(AML)patients,so as to explore new ways for leukemia immunotherapy.Methods:Bone marrow mononuclear cells(BMCs)were isolated from AML complete remission(AML-CR)patients,and were induced to differentiate into DCs by GM-CSF and IL-4 for 7 d.DCs were then divided into 3 groups:LPS positive control group,LNT group,and control group.After 48 h,the morphology of DCs was observed by Wright-Giemsa staining in different groups;CD80,CD83,CD86,CD1α,and HLA-DR expressions on DCs were examined by flow cytometry assay;and IL-12 production was determined by ELISA.DCs of AML patients were isolated from human peripheral blood mononuclear cells(PBMC)by magnetic cell sorting(MACS)after LNT therapy,and the concentration of IL-12 in DC supernatants was determined by ELISA.Results:In vitro,LNT-treated DCs showed a typical DC morphology;it concentration-dependently increased the expressions of CD80,CD83,CD86,CD1a and HLA-DR(P0.05)and level of IL-12 compared with the control group(P0.05).In vivo,IL-12 in the supernatant of DCs of AML patients after LNT therapy was significantly higher than that of untreated patients(P0.05).Conclusion:LNT can promote maturation and function of DCs from AML patients in vivo and in vitro,exrting its anti-tumor effect.